Download Now - The Burrill Report

More documents

Recommendations

Info

SEPTEMBER STATISTICSThe Burrill Report❱❱ (continued)September 2012 Public FinancingsCOMPANY TICKER AMOUNT RAISED (USD M) PRINCIPAL FOCUSOlympus (Japan) Tokyo:7733 645.0 Sony takes 11.5 percent stakeBioLineRx (Israel) BLRX 15.0 Stock purchase agreementDiaMedica (Canada) TSX-V:DMA 1.7 Warrant exerciseTOTAL NON-U.S. OTHER EQUITY 661.7TOTAL SEPTEMBER OTHER EQUITY 738.9DEBTWatson Pharmaceuticals WPI 3,900.0 TherapeuticsMerck MRK 2,500.0 TherapeuticsAgilent Technologies NYSE:A 400.0 Tools/TechnologyCatalent Pharma Solutions Private 350.0 Tools/TechnologySequenom SQNM 130.0 DiagnosticsMedPro Safety Products OTC:MPSP 0.7 Medical devicesTOTAL U.S. DEBT 7,280.7Valeant Pharmaceuticals (Canada) VRX 2,300.0 TherapeuticsAlkermes (Ireland) ALKS 375.0 TherapeuticsElan (Ireland) ELN 600.0 TherapeuticsTOTAL NON-U.S. DEBT 3,275.0TOTAL SEPTEMBER DEBT 10,555.7OTHER DEBTXDx Private 15.0 Senior credit facilityKaloBios Private 10.0 Long-term debt financingAviir Diagnostic Laboratories Private 8.0 Growth debt capital and credit lineUnigene Laboratories OTC:UGNE 4.0 Forebearance agreement and loanFreedom Meditech Private 2.0 Credit facilityTengion OTC:TNGN 1.0 Bridge loanHemoShear Private 1.0 Loan backed by VirginiaTOTAL U.S. OTHER DEBT 41.0TOTAL SEPTEMBER OTHER DEBT 41.0nNovember 2012 30
SEPTEMBER STATISTICSThe Burrill ReportSeptember 2012 Grants and ContractsCOMPANYAMOUNTRAISED (USD M)PRINICPAL FOCUSFUNDING AGENCYGRANTSStemCells 20.0 Neural stem cells California Institute for Regenerative MedicineElusys Therapeutics 14.5 Anthrax drug trial BARDA additional funding under existingcontractsGnuBIO 4.5 Next-gen sequencing NIH NHGRI Advanced DNA-SequencingTechnology ProgramImmunetics 3.7 Babesia blood screening test National Institutes of HealthGalenea 3.0 Schizophrenia biomarkers NIH NIMH 5-year awardProtein Potential 1.8 Malaria vaccine 3 NIH Phase I SBIR grantsEutropics Pharmaceuticals 1.7 Two cancer PGx tests NCI Phase I and Phase II SBIRWaferGen Bio-systems 1.3 Genetic analysis Luxembourg governmentNeuroCog Trials 1.2 Cognitive services for clinical trials industry NIH NIMH Phase II SBIRChanTest 1.0 Drug safety and discovery assays NHLBI Phase II SBIRGigaGen 1.0 Cell-Seq technology Four grants from NIH and NSFHealionics 0.9 Anti-infective device for hemodialysiscathetersNIH NIGMS Phase II SBIRAduro BioTech 0.9 Prostate cancer vaccine Department of Defense CDMRPOmeros 0.7 Neurological disorders National Institute of Mental HealthBiodel 0.6 Diabetes management NIH SBIRAkonni Biosystems 0.5 Lab-on-a-film microarrays NSF SBIR Phase 2 grantProThera Biologics 0.5 Inflammation; infectious National Institutes of HealthFyodor Biotechnologies 0.5 Urine Malaria test NSF Phase 2 SBIRInfinite Enzymes 0.5 Enzymes for biofuels USDAPrimeraDx 0.3 Cancer assay NCI’s Innovative Molecular TechnologiesProgramNavidea Biopharmaceuticals 0.3 Radio-immuno-guided surgery antibodytargeting agentNIH NCI SBIR Phase ISoligenix 0.3 Chronic GVHD NIH NCI SBIREnsysce Biosciences 0.3 Nano-siRNA drug delivery NIH Phase I SBIRPromentis Pharmaceuticals 0.3 Parkinson’s disease Michael J. Fox FoundationDyadic 0.2 Enzymes for improved nutrition EU Framework Programme 7PolyMedix 0.2 Brilacidin for treatment of oral mucositis National Cancer Institute Phase ISharp Edge Labs 0.2 Biosensor technology NIH and NCIVentria Bioscience 0.1 Acetaminophen OD treatment NIH NIAAA Phase 1 STTRTOTAL U.S. GRANTS 60.8Mutabilis (France) 5.2 HIV antivirals EU Framework Programme 7Arsanis (Austria) 2.0 Anti-infective mAbs Austrian Research Promotion Agencyto-BBB technologies(Netherlands)1.6 Eye diseases EU Framework Programme 7 DRUGSFORDconsortium(continued) ❱❱November 2012 31
Page 2 and 3: The Burrill ReportThe Burrill Repor
Page 5: The Burrill ReportThe Risk and Rewa
Page 10 and 11: The Burrill ReportTHIRD QUARTER STA
Page 12 and 13: THIRD QUARTER STATISTICSThe Burrill
Page 24 and 25: SEPTEMBER STATISTICSThe Burrill Rep
Page 28: SEPTEMBER STATISTICSThe Burrill Rep
Page 39 and 40: PIPELINEThe Burrill Report❱❱ (c
Page 45: PIPELINEThe Burrill Report❱❱ (c
Page 48 and 49: PIPELINEThe Burrill ReportUpcoming
Page 50 and 51: INDICESThe Burrill ReportBurrill Bi

Download Now - The Burrill Report

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?